triazoles has been researched along with ibandronic acid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enomoto, K | 1 |
| Harvey, HA | 1 |
| Hussar, DA | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R | 1 |
| Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK | 1 |
2 review(s) available for triazoles and ibandronic acid
| Article | Year |
|---|---|
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
1 trial(s) available for triazoles and ibandronic acid
| Article | Year |
|---|---|
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles | 2008 |
3 other study(ies) available for triazoles and ibandronic acid
| Article | Year |
|---|---|
New drugs 06, part II.
Topics: Analgesics; Benzeneacetamides; Benzoates; Bone Density Conservation Agents; Deferasirox; Diphosphonates; Docosahexaenoic Acids; Drug Approval; Drug Combinations; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Eicosapentaenoic Acid; gamma-Aminobutyric Acid; Humans; Ibandronic Acid; Iloprost; Indenes; Minocycline; Patient Education as Topic; Phenylacetates; Pregabalin; Tigecycline; Triazoles; Vasodilator Agents | 2006 |
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Letrozole; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Neoplasms; Tomography, X-Ray Computed; Triazoles | 2010 |